KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$0.8.

  • Ionis Pharmaceuticals' EPS (Weighted Average and Diluted) rose 1578.95% to -$0.8 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.69, marking a year-over-year increase of 3073.77%. This contributed to the annual value of -$3.04 for FY2024, which is 1875.48% down from last year.
  • Ionis Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$0.8 in Q3 2025, which was up 1578.95% from $0.68 recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $1.59 for Q4 2021, and its period low was -$1.03 during Q3 2023.
  • For the 5-year period, Ionis Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$0.46, with its median value being -$0.6 (2023).
  • In the last 5 years, Ionis Pharmaceuticals' EPS (Weighted Average and Diluted) tumbled by 107059.27% in 2024 and then surged by 25058.21% in 2025.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $1.59 in 2021, then tumbled by 123.52% to -$0.37 in 2022, then surged by 83.92% to -$0.06 in 2023, then tumbled by 1070.59% to -$0.7 in 2024, then dropped by 13.9% to -$0.8 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.8 in Q3 2025, compared to $0.68 in Q2 2025 and -$0.93 in Q1 2025.